4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Heidelberg Pharma AG (HPHA) operates in the Biotechnology industry and is headquartered in Ladenburg, Germany with about 41 employees. Its market capitalization is roughly €123 million. In the fiscal year ended 2025-11-30, HPHA reported €2M in revenue and (€42M) in net income.
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally.
Interactive charts & full statements →
| Income statement | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Total Revenue | €2M | €7M | €10M | €18M |
| Gross Profit | €1M | €5M | €7M | €14M |
| Operating Income (EBIT) | (€47M) | (€23M) | (€28M) | (€18M) |
| Net Income | (€42M) | (€19M) | (€20M) | (€20M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 |
|---|---|---|---|---|---|
| Total Revenue | €4M | €3M | €0M | €0M | €1M |
| Gross Profit | €4M | €3M | (€0M) | €0M | €1M |
| Operating Income (EBIT) | €0M | (€5M) | (€20M) | (€9M) | (€8M) |
| Net Income | €1M | (€4M) | (€21M) | (€7M) | (€6M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 |
|---|---|---|---|---|---|
| Total Assets | €38M | €61M | €70M | €101M | — |
| Total Liabilities | €49M | €30M | €21M | €34M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HPHA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms